- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03276793
Brain Connectivity in Depression
Using Human Brain Connectivity to Identify the Causal Neuroanatomical Substrate of Depression Symptoms
This study originally included 100 subjects with medication-refractory depression undergoing 10 Hz transcranial magnetic stimulation (10Hz-TMS) to the left dorsal lateral prefrontal cortex (DLPFC), with the goal of having 60 completers with good quality data. Subjects were recruited from the TMS clinics at Beth Israel Deaconess Medical Center, Brigham & Women's Hospital, and Butler Hospital. Subjects underwent an hour-long MRI scanning session, an optional DNA-sample collection, up to three 20 minute neuronavigation sessions for marking the site of TMS stimulation, questionnaires, and a behavioral testing battery before and after their TMS treatment course. The task battery included the Emotion Conflict Resolution (ECR) task, Multi-Source Interference Task (MSIT), War Game (Gambling) task, and Associative Learning with Reversal task. Subjects' scores on the Quick Inventory of Depressive Symptomatology (QIDS) and Beck Depression Inventory (BDI) were assessed before and after the TMS course. MRI data was utilized to identify brain regions whose connectivity to the stimulation site co-varies with the aforementioned measures of symptom improvement. This was the only study group until August 30, 2022, and the primary outcome was analyzed for the 10Hz-TMS group.
Due to changes in clinical standard of care from 10Hz-TMS to a newer version of TMS termed intermittent theta burst (iTBS), in September 2022 a second group was added to include patients receiving this new form of TMS. This second group included another 100 patients with medication-refractory depression undergoing iTBS to the left dorsal lateral prefrontal cortex (DLPFC), with the intent to have 80 completers. Massachusetts General Hospital was added as a data collection site in lieu of Butler Hospital. Subjects will undergo an hour-long MRI scanning session, up to three 20 minute neuronavigation sessions for marking the site of TMS stimulation, questionnaires, and a behavioral testing battery before and after their TMS treatment course. The task battery will included the Emotion Conflict Resolution (ECR) task, Multi-Source Interference Task (MSIT), Penn Emotion Recognition Test, the Suicide/Death Implicit Association Test, and Associative Learning with Reversal task. Subjects' scores on the Beck Depression Inventory (BDI) were assessed before and after the TMS course. MRI data will be utilized to identify brain regions whose connectivity to the stimulation site co-varies with the aforementioned measures of symptom improvement.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This study was originally approved by the Beth Israel Deaconess Medical Center (BIDMC) Institutional Review Board (IRB) with Butler Hospital as a relying site. The study was transferred to the Mass General Brigham (MGB) IRB in 2020 when Dr. Fox (lead PI) moved to Brigham and Women's Hospital (BWH). Butler Hospital continued to enroll subjects, relying on the MGB IRB for regulatory oversight, while BIDMC stopped enrolling subjects. A Data Usage Agreement was established between BIDMC and BWH, and all previously collected Data was de-identified and sent to BWH. The protocol at BIDMC will remain active but not enrolling until all the de-identified data has been sent to BWH.
In Sept 2022, with the launch of the second iTBS group, Massachusetts General Hospital replaced Butler Hospital as the secondary enrollment site, while enrollment continued at Brigham and Women's Hospital.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Stephan Palm, BS
- Phone Number: 617-732-6658
- Email: bwhtmstrials@bwh.harvard.edu
Study Contact Backup
- Name: Maya Pattin, BS
- Email: bwhtmstrials@bwh.harvard.edu
Study Locations
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Recruiting
- Brigham and Women's Hospital
-
Contact:
- Michael D Fox, MD, PhD
- Phone Number: 617-732-7432
- Email: mdfox@bwh.harvard.edu
-
Principal Investigator:
- Michael D Fox, MD, PhD
-
Sub-Investigator:
- Joseph J Taylor, MD, PhD
-
Sub-Investigator:
- Shan H Siddiqi, MD
-
Sub-Investigator:
- Stephan T Palm, BS
-
Sub-Investigator:
- Christopher Lin, BS
-
Sub-Investigator:
- Dania Haj-Darwish, BS
-
Sub-Investigator:
- Summer B Frandsen, BS
-
Sub-Investigator:
- William Drew, BS
-
Sub-Investigator:
- Sanaz Khosravani, PhD
-
Boston, Massachusetts, United States, 02215
- Completed
- Beth Israel Deaconess Medical Center
-
Boston, Massachusetts, United States, 02129
- Recruiting
- Massachusetts General Hospital
-
Contact:
- Tracy A Barbour, MD
- Phone Number: 617-726-5340
- Email: TBARBOUR@PARTNERS.ORG
-
Principal Investigator:
- Tracy A Barbour, MD
-
Principal Investigator:
- Joan A Camprodon, MD, MPH, PhD
-
Sub-Investigator:
- Nicole L Brocious, BS
-
Sub-Investigator:
- Christopher J Funes, MS
-
Sub-Investigator:
- James R Coleman, BS
-
Sub-Investigator:
- Anna Moser, MS
-
Sub-Investigator:
- Olivia J Newman, BS
-
Sub-Investigator:
- Astrid Warney, MS
-
Contact:
- Stephanie R Kramer, BS
- Email: SKRAMER5@mgh.harvard.edu
-
Sub-Investigator:
- Stephanie R Kramer, BS
-
-
Rhode Island
-
Providence, Rhode Island, United States, 02906
- Active, not recruiting
- Butler Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female
- Aged 18-70.
- Have previously received or will receive TMS to the left dorsal-lateral prefrontal cortex as part of the clinical treatment program at the Center for Brain Circuit Therapeutics at Brigham and Women's Hospital, or at Massachusetts General Hospital for treatment of medication resistant depression
Exclusion Criteria:
- History of bipolar disorder (lifetime), schizophrenia or psychosis (lifetime), obsessive-compulsive disorder (unstable in past six months), posttraumatic stress disorder (unstable in past six months), eating disorders (unstable in past six months), or moderate to severe substance use disorders (currently active, with the exception of nicotine and cannabis)
- Presence of a significant neurologic disorder (i.e. Parkinson's Disease, stroke, Alzheimer's Disease, tumor, multiple sclerosis, epilepsy). Of note, many of these are also contraindications to receiving TMS and these patients would not be enrolled in the clinical treatment program.
- Patients who are pregnant or lactating (by menstrual history)
- Current abuse of an illicit substance (e.g. marijuana, cocaine, heroin, hallucinogens, psychostimulants)
Positive MRI screen that would preclude the subject from undergoing magnetic resonance imaging. These include, but are not limited to any of the following:
- Known metal in the head (such as a surgical aneurysm clip), or a history of prior neurosurgical procedures
- Ferromagnetic bioimplants activated by any electronic, mechanical or magnetic means such as: cochlear implants, pacemakers, medication pumps, vagal stimulators, deep brain stimulators, neurostimulators, biostimulators, or ventriculo-peritoneal shunts
- Subjects who have or might have bullet fragments or other metal fragments (veterans or workers exposed to metal in their work environment)
- Subjects with metallic paint (e.g. color contact lenses, tattoos, metallic eyeliner)
- Subjects expressing significant anxiety or claustrophobia about being in the magnet.
- Subjects that cannot adhere to the experimental protocol for any reason.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: MRI and behavioral assessment for patients receiving TMS
Subjects will undergo an hour-long MRI scanning session, a marking for the site of planned clinical TMS stimulation and a behavioral testing battery before and after their TMS treatment course.
|
Patients will undergo an MRI scan
Patients will complete a series of cognitive tasks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Prediction of repetitive Transcranial Magnetic Stimulation (rTMS) clinical response
Time Frame: 1 year after study completion
|
Connectivity between each patient's stimulation site and the subgenual cingulate will be used to predict clinical response to rTMS in the first group (data collected starting in 2017).
|
1 year after study completion
|
Prediction of intermittent theta burst stimulation (iTBS) clinical response
Time Frame: 1 year after study completion
|
Normative connectivity of each patient's stimulation site to a previously-published "depression network" (Siddiqi et al., Nat Hum Behav 2021) will be used to predict clinical response to iTBS in the second group added in September 2022.
|
1 year after study completion
|
Collaborators and Investigators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2021P000335
- R01MH113929 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Depression
-
ProgenaBiomeRecruitingDepression | Depression, Postpartum | Depression, Anxiety | Depression Moderate | Depression Severe | Clinical Depression | Depression in Remission | Depression, Endogenous | Depression ChronicUnited States
-
Washington University School of MedicineCompletedTreatment Resistant Depression | Late Life Depression | Geriatric Depression | Refractory Depression | Therapy-Resistant DepressionUnited States, Canada
-
University of California, San FranciscoRecruitingDepression Moderate | Depression Mild | Depression, TeenUnited States
-
University GhentUniversiteit Antwerpen; Janssen-Cilag Ltd.RecruitingDepression Moderate | Depression Severe | Depression MildBelgium
-
Baylor College of MedicineUniversity of TexasRecruitingDepression | Depression Moderate | Depression Severe | Suicide and Self-harm | Depression in Adolescence | Depression MildUnited States
-
University of Cape TownNational Institute of Mental Health (NIMH)CompletedPostpartum Depression | Clinical Depression | Moderate DepressionSouth Africa
-
Washington University School of MedicinePatient-Centered Outcomes Research Institute; National Institute of Mental...CompletedMajor Depressive Disorder | Treatment Resistant Depression | Treatment-Refractory Depression | Late Life Depression | Geriatric DepressionUnited States, Canada
-
Northern Illinois UniversityUniversity Autonoma de Santo DomingoTerminatedDepression Moderate | Depression MildUnited States, Dominican Republic
-
Gerbera Therapeutics, Inc.Not yet recruitingPostpartum Depression | Depression, Postpartum | Postnatal Depression | Post-partum Depression | Post-Natal DepressionUnited States
-
Lawson Health Research InstituteTerminated
Clinical Trials on MRI scan
-
University of ChicagoRecruitingBreast CancerUnited States
-
Jeffrey A. Lieberman, MDTerminated
-
New York State Psychiatric InstituteNational Institute of Mental Health (NIMH)TerminatedSchizophreniaUnited States
-
Radboud University Medical CenterCompletedHead and Neck NeoplasmsNetherlands
-
The Clatterbridge Cancer Centre NHS Foundation...Unknown
-
University of LeicesterNational Institute for Health Research, United KingdomCompletedPatients With Heart Failure and Preserved Ejection Fraction - HFpEF | Patients With Heart Failure With Reduced Ejection Fraction - HFrEF | Healthy Controls Group - Age and Sex-matched
-
Amsterdam UMC, location VUmcMRIguidance B.V.CompletedSinusitis | Hearing Loss | Head and Neck Tumor | Cholesteatoma | Imaging of Bony Structures of the Head (Various Conditions)Netherlands
-
West China HospitalRecruiting
-
Imperial College LondonRecruitingDiastolic DysfunctionUnited Kingdom
-
University Hospitals Bristol and Weston NHS Foundation...Bosum Buddies; Friends of the Bristol Haematology and Oncology CentreTerminated